Julie Ozier, MHL, CIP, CHRC

SVP for Regulatory Review, Advarra

Julie Ozier has over 20 years of experience in the human research protections and research compliance area. At Advarra, she has operational oversight of the IRB Review/Regulatory team and provides senior regulatory leadership. Previously, Ozier served as the Director of the Human Research Protections Program at Vanderbilt University and Medical Center. Additionally, she also served as a site visitor and council member for AAHRPP and is active in the HRPP community. Ozier has a Master’s in Health Law and is a Certified IRB Professional and Certified in Healthcare Research Compliance.

Latest Posts by Julie Ozier

Clinical research professionals talking and gesturing to a laptop

2026 DHHS Unified Agenda: Four Areas HRPP and IRB Leaders Should Watch

The U.S. Office of Information and Regulatory Affairs (OIRA), within the Office of Management and...

Read More...

2026 DHHS Unified Agenda: What Clinical Operations and Study Startup Teams Should Watch

Planned changes outlined in the U.S. federal government’s 2026 Regulatory Plan and the Unified Agenda...

Read More...

2026 DHHS Unified Agenda: What Clinical Research Leaders Need to Know

On July 3, 2026, the U.S. Office of Information and Regulatory Affairs (OIRA), within the...

Read More...

The Belmont Report Still Shapes How IRBs Protect Human Research Subjects Today

With all the buzz recently on regulatory reform for institutional review boards (IRBs), it’s worth...

Read More...

Why Should Local IRBs and HRPPs Collaborate with External IRBs? 

Multisite research and clinical trials increasingly rely on a single IRB (sIRB) for review. This increase reflects federal mandates, sponsor expectations,...

Read More...

What is a Quality IRB Review?

Metrics in general are one of the ways we can gauge how well a program...

Read More...

Your Guide to sIRB Mandates

In the past few years, new regulations and policies have been announced and implemented to...

Read More...
FDA’s September 2022 NPRMs – What They Mean for Academia and Industry

FDA’s September 2022 NPRMs: What They Mean for Academia and Industry

On September 28, 2022, the Food and Drug Administration (FDA) released two Notices of Proposed...

Read More...

Why do Funding and Legal Structure Matter in Decentralized Clinical Trials?

Optimizing clinical trial access for potential patients is a critical goal for researchers and sponsors....

Read More...

What do I do About Incidental Findings in Research?

An incidental finding is a “finding” or result from an intervention or test that uncovers...

Read More...

Considerations for IRB Review: Artificial Intelligence & Machine Learning

Artificial intelligence in clinical research is expanding rapidly, bringing both excitement and ethical challenges. How...

Read More...

Local Versus Central IRBs: What’s the Difference?

Central and local IRBs share the same research oversight goals, but NIH’s single IRB mandate...

Read More...
Login
Scroll to Top